Drug intelligence / Profile preview

KLH-adrenomedullin mRNA vaccine

Development stage
Preclinical
Modality
Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intramuscular
01

Overview

The KLH-adrenomedullin mRNA vaccine is an experimental cancer immunotherapy designed to target adrenomedullin (AM), a regulatory peptide overexpressed in many solid tumors that promotes angiogenesis and tumor growth. The vaccine utilizes in vitro-synthesized mRNA encoding a fusion protein of keyhole limpet hemocyanin (KLH) and adrenomedullin, encapsulated in lipid nanoparticles (LNPs). By acting as a hapten, the KLH component helps break peripheral immunotolerance to the self-antigen adrenomedullin. Administered via intramuscular injection, the vaccine elicits both humoral (anti-AM IgG antibodies) and cellular (CD8+ T cell) immune responses. Preclinical studies in melanoma models have demonstrated its ability to inhibit tumor angiogenesis and reduce tumor volume and metastasis without significant systemic toxicity.

Other names
KLH-AM mRNA vaccineKLH-adrenomedullin mRNA-LNP vaccine
02

Targets

ADM (Adrenomedullin)

Beyond the preview

Go deeper on KLH-adrenomedullin mRNA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KLH-adrenomedullin mRNA vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call